Voya Investment Management LLC cut its position in Waters Corporation (NYSE:WAT - Free Report) by 15.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 549,919 shares of the medical instruments supplier's stock after selling 104,048 shares during the quarter. Voya Investment Management LLC owned about 0.56% of Waters worth $240,943,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC lifted its holdings in shares of Waters by 3.5% during the third quarter. Ashton Thomas Securities LLC now owns 704 shares of the medical instruments supplier's stock worth $309,000 after buying an additional 24 shares in the last quarter. Caitlin John LLC grew its stake in shares of Waters by 43.9% in the second quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier's stock valued at $31,000 after acquiring an additional 25 shares in the last quarter. Park Avenue Securities LLC grew its stake in shares of Waters by 2.8% in the third quarter. Park Avenue Securities LLC now owns 910 shares of the medical instruments supplier's stock valued at $400,000 after acquiring an additional 25 shares in the last quarter. Kingswood Wealth Advisors LLC grew its stake in shares of Waters by 3.7% in the third quarter. Kingswood Wealth Advisors LLC now owns 786 shares of the medical instruments supplier's stock valued at $345,000 after acquiring an additional 28 shares in the last quarter. Finally, Kestra Investment Management LLC increased its position in Waters by 4.0% during the third quarter. Kestra Investment Management LLC now owns 783 shares of the medical instruments supplier's stock worth $344,000 after acquiring an additional 30 shares during the period. 94.01% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages have weighed in on WAT. Royal Bank Of Canada lifted their price objective on shares of Waters from $475.00 to $525.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. increased their target price on shares of Waters from $435.00 to $470.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. Evercore increased their target price on shares of Waters from $410.00 to $480.00 in a research report on Wednesday, October 7th. Wall Street Zen cut shares of Waters from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Leerink Partners lifted their price target on shares of Waters from $420.00 to $450.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $475.48.
Read Our Latest Stock Report on WAT
Waters Stock Performance
NYSE:WAT opened at $449.28 on Wednesday. The company has a market cap of $44.16 billion, a price-to-earnings ratio of 192.82, a PEG ratio of 2.58 and a beta of 1.16. Waters Corporation has a fifty-two week low of $282.77 and a fifty-two week high of $483.33. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.28 and a current ratio of 1.89. The stock has a fifty day moving average price of $442.24 and a 200-day moving average price of $374.83.
Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 EPS for the quarter, topping analysts' consensus estimates of $4.00 by $0.10. The company had revenue of $1.77 billion for the quarter, compared to analysts' expectations of $1.75 billion. Waters had a return on equity of 9.91% and a net margin of 1.75%. Waters's revenue was up 120.9% on a year-over-year basis. During the same quarter last year, the business earned $3.40 earnings per share. As a group, equities analysts anticipate that Waters Corporation will post 14.65 EPS for the current fiscal year.
Waters Profile
(
Free Report)
Waters Corporation develops and supplies analytical instruments, software, and consumables used to identify, measure, and characterize chemical and biological materials. Its products include liquid chromatography and mass spectrometry systems, which help customers analyze complex samples. The company serves pharmaceutical and biotechnology businesses, academic and government laboratories, and customers in fields such as food, environmental testing, and materials science. Waters operates internationally, with customers and operations across multiple regions.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.